Affymetrix tech to be used in new gene study

India's Avesthagen has inked a deal to use Affymetrix's microarray technology in a genetic study involving 60,000 Parsi. The Avestagenome Project is studying the genetic foundation behind longevity. Almost a third of the Parsi population lives beyond the age of 60, compared to seven percent of the country's entire population.

- see this release
- read the story in the San Jose Business Journal

Related Articles:
Affymetrix to acquire ParAllele in $120M deal. Report
Longevity gene may be key to living past 100. Report
Biotechs pursue anti-aging treatments. Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.